v3.26.3
Liquidity (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Proceeds from the exercise of common stock warrants and pre-funded warrants       $ 85,142 $ 8,712  
Exercised (in shares)       50,400,000    
Exercise price (in dollars per share)   $ 1.69   $ 1.69    
Cash and cash equivalents   $ 134,711   $ 134,711   $ 71,793
Restricted cash and cash equivalents   100   100   100
Accumulated deficit   303,091   303,091   $ 274,988
Net loss   $ 10,091 $ 6,791 28,103 19,205  
Net cash used in operating activities       $ 22,374 $ 23,468  
At-The-Market Equity Offering Program (2026 ATM)            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Net proceeds of common stock $ 150,000          
Number of shares of common stock sold (in shares)       0